SSRScientific and Social Research2661-43322981-9946Bio-Byword Scientific Publishing Pty. Ltd.10.26689/ssr.v8i8.15234ArticleResearch Progress on Artificial Intelligence-Based Early Diagnosis and Treatment of Alzheimer's Diseasehttps://artdesignp.com/journal/SSR/8/8/10.26689/ssr.v8i8.15234ShaRoujia,FengWeike2026882026-08-31Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases and continues to place a considerable burden on public health systems worldwide. Owing to its complicated pathological mechanisms, difficulties associated with early diagnosis, and the lack of treatments capable of halting disease progression, AD remains a major focus of current research. In recent years, artificial intelligence (AI) has increasingly been introduced into this field. Methods based on machine learning, deep learning, and the integration of different types of data have shown potential in several aspects of AD research and clinical care. Existing studies have explored the use of AI for identifying AD at earlier stages, analyzing neuroimaging data, estimating disease progression, supporting digital health interventions, and assisting drug development. This review summarizes recent work in these areas and focuses on several topics that have attracted particular attention, such as neuroimaging applications, biomarker discovery, cognitive and behavioral evaluation, long-term disease monitoring, and therapeutic support. At the same time, a number of issues continue to limit wider clinical adoption. Differences in data sources, insufficient generalizability of some models, and concerns regarding ethics, privacy, and data security are among the challenges most frequently discussed in the literature. Addressing these problems will be important for the future development and practical use of AI-based approaches in AD diagnosis and management.Alzheimer’s disease, Artificial intelligence, Machine learning, Deep learning, Neuroimaging, Blood biomarkers

[1] Jack CR, Bennett AD, Blennow K, et al., 2018, NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 14(4): 535–562. https://doi.org/10.1016/j.jalz.2018.02.018 [2] Leng FD, Edison P, 2020, Neuroinflammation and Microglial Activation in Alzheimer Disease: Where Do We Go from Here? Nature Reviews Neurology, 17(3): 157–172. https://doi.org/10.1038/S41582-020-00435-Y [3] Kobayashi G, Hirata K, Ono M, et al., 2026, The 2024 NIA-AA Biological Definition of Alzheimer’s Disease: Linking Biomarkers to Clinical Practice. Frontiers in Dementia, 2026(5): 1736297. https://doi.org/10.3389/FRDEM.2026.1736297 [4] Wang G, Qi JL, Liu XY, et al., 2024, China Alzheimer’s Disease Report 2024. Journal of Diagnostics Concepts & Practice, 23(3): 219–256. https://doi.org/10.16150/j.1671-2870.2024.03.001 [5] Wang NB, Ma XW, Wang GH, et al., 2025, Chinese Expert Consensus on Multi-Dimensional Rehabilitation Interventions for Alzheimer’s Disease (2025). Journal of Alzheimer’s Disease and Related Disorders, 8(3): 147–163 + 187 + 145. [6] Qiu XR, Zhang YD, Yang GF, 2026, Application of Multimodal Artificial Intelligence in the Early Diagnosis of Alzheimer’s Disease: Current Status, Challenges, and Clinical Translation Pathways. The Journal of Practical Medicine, 42(9): 1579–1585. [7] Arya AD, Verma SS, Chakarabarti P, et al., 2023, A Systematic Review on Machine Learning and Deep Learning Techniques in the Effective Diagnosis of Alzheimer’s Disease. Brain Informatics, 10(1): 17. https://doi.org/10.1186/S40708-023-00195-7 [8] Du YZ, Cao H, Nie YQ, et al., 2023, Application of Deep Learning in Classification Diagnosis of Alzheimer’s Disease. Computer Engineering and Applications, 59(3): 49–65. [9] Pan D, Zeng A, Yang BY, et al., 2022, Deep Learning for Brain MRI Confirms Patterned Pathological Progression in Alzheimer’s Disease. Advanced Science, 10(6): e2204717. https://doi.org/10.1002/ADVS.202204717 [10] Xue C, Kowshik SS, Lteif D, et al., 2024, AI-based Differential Diagnosis of Dementia Etiologies on Multimodal Data. Nature Medicine, 30(10): 2977–2989. https://doi.org/10.1038/S41591-024-03118-Z [11] Du XS, Laurentiev JN, Plasek JM, et al., 2024, Enhancing Early Detection of Cognitive Decline in the Elderly through Ensemble of NLP Techniques: A Comparative Study Utilizing Large Language Models in Clinical Notes. medRxiv. https://doi.org/10.1101/2024.04.03.24305298 [12] Treder MS, Lee S, Tsvetanov KA, 2024, Introduction to Large Language Models (LLMs) for Dementia Care and Research. Frontiers in Dementia, 2024(3): 1385303. https://doi.org/10.3389/FRDEM.2024.1385303 [13] Pan P, Lu J, 2024, Application of Magnetic Resonance Imaging Based on Deep Learning in the Diagnosis of Alzheimer’s Disease. Bachu Medical Journal, 7(3): 118–124. [14] Qian CY, Wang YJ, 2023, Research Progress of Imaging Classification of Alzheimer’s Disease Based on Deep Learning. Chinese Journal of Magnetic Resonance, 40(2): 220–238. [15] Hu WQ, Du QH, Wei LS, et al., 2025, Novel Multi-task Learning for Alzheimer’s Stage Classification using Hippocampal MRI Segmentation, Feature Fusion, and Nomogram Modeling. European Journal of Medical Research, 30(1): 910. https://doi.org/10.1186/S40001-025-03204-Z [16] Lee J, Burkett BJ, Min HK, et al., 2023, Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning. Brain: A Journal of Neurology, 147(3): 1060–1074. https://doi.org/10.1093/BRAIN/AWAD346 [17] Cao GP, Yuan XT, Zhang YT, et al., 2025, Diagnosis Method of Alzheimer’s Disease Based on Dual-pathway Convolutional Network and Adaptive Feature Fusion. Journal of Beijing University of Posts and Telecommunications, 48(5): 105–111 + 172. https://doi.org/10.13190/j.jbupt.2024-206 [18] Chen C, Chen J, Xia LM, 2024, Artificial Intelligence Promotes Clinical Application and Research of Medical Imaging. Radiological Practice, 39(1): 12–16. https://doi.org/10.13609/j.cnki.1000-0313.2024.01.003 [19] Palmqvist S, Tideman P, Mattsson-Carlgren N, et al., 2024, Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA, 332(8): 650–659. https://doi.org/10.1001/JAMA.2024.13855 [20] Li ML, Che P, Liu DQ, et al., 2025, Diagnostic and Discriminative Accuracy of Plasma Phosphorylated tau 217 for Symptomatic Alzheimer’s Disease in a Chinese Cohort. The Journal of Prevention of Alzheimer’s Disease, 12(5): 100092. https://doi.org/10.1016/J.TJPAD.2025.100092 [21] Barthélemy NR, Salvadó G, Schindler S, et al., 2024, Highly Accurate Blood Test for Alzheimer’s Disease Comparable or Superior to Clinical CSF Tests. Nature Medicine, 30(4): 1085–1095. https://doi.org/10.1038/S41591-024-02869-Z [22] Suárez-Calvet M, Salvadó G, Bilbeny de Fortuny B, et al., 2026, Blood Biomarkers for Alzheimer’s Disease: From Detection to Decisions. The Lancet, 407(10544): 2151–2154. https://doi.org/10.1016/S0140-6736(26)00909-8 [23] Cai HM, Pang YN, Fu XF, et al., 2023, Plasma Biomarkers Predict Alzheimer’s Disease before Clinical Onset in Chinese Cohorts. Nature Communications, 14(1): 6747. https://doi.org/10.1038/S41467-023-42596-6 [24] Zhang MG, 2025, Exploring the Novel Pathological Significance of Alzheimer’s Disease Biomarkers Based on Fluid Biomarkers and Multimodal Imaging, thesis, University of Science and Technology of China. https://doi.org/10.27517/d.cnki.gzkju.2025.002436 [25] Jasodanand VH, Kowshik SS, Puducheri S, et al., 2025, AI-Driven Fusion of Multimodal Data for Alzheimer’s Disease Biomarker Assessment. Nature Communications, 16(1): 7407. https://doi.org/10.1038/S41467-025-62590-4 [26] Hajjar I, Okafor M, Choi JD, et al., 2023, Development of Digital Voice Biomarkers and Associations with Cognition, Cerebrospinal Biomarkers, and Neural Representation in Early Alzheimer’s Disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 15(1): e12393. https://doi.org/10.1002/DAD2.12393 [27] García-Gutiérrez F, Alegret M, Marquié M, et al., 2024, Unveiling the Sound of the Cognitive Status: Machine Learning-based Speech Analysis in the Alzheimer’s Disease Spectrum. Alzheimer’s Research & Therapy, 16(1): 26. https://doi.org/10.1186/S13195-024-01394-Y [28] Qi W, Zhu X, Wang B, et al., 2025, Alzheimer’s Disease Digital Biomarkers Multidimensional Landscape and AI Model Scoping Review. NPJ Digital Medicine, 2025(8): Article 366. https://doi.org/10.1038/s41746-025-01640-z [29] Ran LF, Nie ZQ, Guo JH, 2024, Research Progress of Digital Technology in Alzheimer’s Disease. Tianjin Medical Journal, 52(10): 1106–1110. [30] Mattsson-Carlgren N, Salvadó G, Ashton NJ, et al., 2023, Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurology, 80(4): 360–369. https://doi.org/10.1001/jamaneurol.2022.5272 [31] Lee MW, Kim HW, Choe YS, et al., 2024, A Multimodal Machine Learning Model for Predicting Dementia Conversion in Alzheimer’s Disease. Scientific Reports, 14(1): 12276. https://doi.org/10.1038/S41598-024-60134-2 [32] Karlsson L, Vogel J, Arvidsson I, et al., 2025, Machine Learning Prediction of tau-PET in Alzheimer’s Disease Using Plasma, MRI, and Clinical Data. Alzheimer’s & Dementia, 21(3): e14600. https://doi.org/10.1002/alz.14600 [33] Li Q, Yang X, Xu J, et al., 2023, Early Prediction of Alzheimer’s Disease and Related Dementias Using Real-world Electronic Health Records. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 19(8): 3506–3518. https://doi.org/10.1002/ALZ.12967 [34] Han YM, Li IJ, Zhang H, et al., 2025, Value of Deep Learning in Neuroradiology Research for Predicting Conversion of Alzheimer’s Disease. The Journal of Practical Medicine, 41(9): 1413–1424. [35] Shaik MA, Anik FI, Hasan MM, et al., 2025, Advancing Remote Monitoring for Patients with Alzheimer Disease and Related Dementias: Systematic Review. JMIR Aging, 2025(8): e69175. https://doi.org/10.2196/69175 [36] Cheng FX, Wang F, Tang J, et al., 2024, Artificial Intelligence and Open Science in Discovery of Disease-Modifying Medicines for Alzheimer’s Disease. Cell Reports Medicine, 5(2): 101379. https://doi.org/10.1016/J.XCRM.2023.101379 [37] Abramson J, Adler J, Dunger J, et al., 2024, Accurate Structure Prediction of Biomolecular Interactions with AlphaFold 3. Nature, 630(8016): 493–500. https://doi.org/10.1038/S41586-024-07487-W [38] Li VOK, Han Y, Kaistha T, et al., 2025, DeepDrug as an Expert Guided and AI Driven Drug Repurposing Methodology for Selecting the Lead Combination of Drugs for Alzheimer’s Disease. Scientific Reports, 2025(15): 2093. https://doi.org/10.1038/s41598-025-85947-7 [39] Zhang P, Zhang DF, Zhou WA, et al., 2023, Network Pharmacology: Towards the Artificial Intelligence-based Precision Traditional Chinese Medicine. Briefings in Bioinformatics, 25(1): bbad518. https://doi.org/10.1093/BIB/BBAD518 [40] Chang QQ, Zhuang YY, Lu YY, et al., 2026, Mechanism Analysis of Babao Yizhi Formula in Improving Alzheimer’s Disease Based on Network Pharmacology and Molecular Docking Technology. New Journal of Traditional Chinese Medicine, 58(1): 197–203. https://doi.org/10.13457/j.cnki.jncm.2026.01.033 [41] Mittermaier M, Raza MM, Kvedar JC, 2023, Bias in AI-based Models for Medical Applications: Challenges and Mitigation Strategies. NPJ Digital Medicine, 6(1): 113. https://doi.org/10.1038/S41746-023-00858-Z [42] Khosroshahi MT, Morsali S, Gharakhanlou S, et al., 2025, Explainable Artificial Intelligence in Neuroimaging of Alzheimer’s Disease. Diagnostics, 15(5): 612. https://doi.org/10.3390/DIAGNOSTICS15050612 [43] Muehlematter UJ, Bluethgen C, Vokinger KN, 2023, FDA-cleared Artificial Intelligence and Machine Learning-based Medical Devices and their 510(k) Predicate Networks. The Lancet Digital Health, 5(9): e618–e626. https://doi.org/10.1016/S2589-7500(23)00126-7 [44] Liu L, Zhang X, Zhang QQ, et al., 2025, Ethical Risk Identification, Governance, and Prospective Research on Large Models in the Medical Field. Strategic Study of CAE, 27(6): 54–67. [45] Pan JQ, Fan ZK, Smith GE, et al., 2025, Federated Learning with Multi-cohort Real-World Data for Predicting the Progression from Mild Cognitive Impairment to Alzheimer’s Disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 21(4): e70128. https://doi.org/10.1002/ALZ.70128